-$0.48 EPS Expected for Ra Pharmaceuticals Inc (NASDAQ:RARX) This Quarter
Brokerages forecast that Ra Pharmaceuticals Inc (NASDAQ:RARX) will report earnings per share of ($0.48) for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Ra Pharmaceuticals’ earnings, with estimates ranging from ($0.52) to ($0.45). Ra Pharmaceuticals posted earnings of ($0.49) per share in the same quarter last year, which would suggest a positive year-over-year growth rate of 2%. The business is scheduled to announce its next earnings results on Wednesday, August 14th.
On average, analysts expect that Ra Pharmaceuticals will report full year earnings of ($1.98) per share for the current fiscal year, with EPS estimates ranging from ($2.21) to ($1.87). For the next fiscal year, analysts forecast that the business will post earnings of ($2.43) per share, with EPS estimates ranging from ($2.87) to ($1.90). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research analysts that cover Ra Pharmaceuticals.
Ra Pharmaceuticals (NASDAQ:RARX) last released its earnings results on Thursday, May 9th. The company reported ($0.45) EPS for the quarter, beating the consensus estimate of ($0.47) by $0.02.
Several large investors have recently modified their holdings of the stock. RA Capital Management LLC lifted its position in Ra Pharmaceuticals by 26.1% in the 4th quarter. RA Capital Management LLC now owns 4,858,260 shares of the company’s stock worth $33,963,000 after buying an additional 1,006,452 shares in the last quarter. BlackRock Inc. lifted its position in Ra Pharmaceuticals by 29.0% in the 4th quarter. BlackRock Inc. now owns 2,645,261 shares of the company’s stock worth $48,142,000 after buying an additional 595,328 shares in the last quarter. Sectoral Asset Management Inc lifted its position in Ra Pharmaceuticals by 129.3% in the 4th quarter. Sectoral Asset Management Inc now owns 799,612 shares of the company’s stock worth $14,553,000 after buying an additional 450,900 shares in the last quarter. Candriam Luxembourg S.C.A. lifted its position in Ra Pharmaceuticals by 102.1% in the 4th quarter. Candriam Luxembourg S.C.A. now owns 879,000 shares of the company’s stock worth $15,997,000 after buying an additional 444,000 shares in the last quarter. Finally, FMR LLC lifted its position in Ra Pharmaceuticals by 454.2% in the 4th quarter. FMR LLC now owns 413,389 shares of the company’s stock worth $7,524,000 after buying an additional 338,801 shares in the last quarter. Institutional investors and hedge funds own 94.97% of the company’s stock.
RARX stock traded up $0.27 on Friday, hitting $21.26. 405,700 shares of the company’s stock traded hands, compared to its average volume of 414,758. Ra Pharmaceuticals has a 1-year low of $8.27 and a 1-year high of $27.68. The firm has a market cap of $882.87 million, a PE ratio of -10.32 and a beta of 0.80. The company has a debt-to-equity ratio of 0.02, a current ratio of 20.10 and a quick ratio of 20.10.
Ra Pharmaceuticals Company Profile
Ra Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules.
Read More: How Do Tariffs Affect Trade Balances?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ra Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.